login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

UK’s NICE encourages research on percutaneous venoplasty for multiple sclerosis


Monday, 02 Apr 2012 13:00

Final guidance from the UK’s National Institute for Health and Clinical Excellence (NICE), released on 28 March, encourages further research into percutaneous venoplasty, a procedure which is claimed to relieve symptoms for some people with multiple sclerosis.


The procedure aims to improve blood flow from the brain by using a small inflatable balloon to widen narrowed veins in the neck which carry oxygen-depleted blood. It has been suggested that there could be a link between narrowed veins (called chronic cerebrospinal venous insufficiency, or CCSVI) and the progression of multiple sclerosis.

NICE’s guidance advises the procedure should be only performed on these patients in the context of clinical research. This is so that more evidence on its safety and efficacy can be developed; for example to explore the impact that the procedure could have on quality of life in the long term.

Professor Bruce Campbell, chair of the independent committee that develops NICE’s interventional procedures guidance said: “Multiple sclerosis can be a distressing and disabling condition with a lack of effective treatments. This means that it is really important to find out whether percutaneous venoplasty is clinically effective and safe for use in the NHS. Based on the existing evidence, we believe that clinicians should only consider offering percutaneous venoplasty as a treatment option for people with multiple sclerosis who fit the diagnostic criteria for CCSVI, as part of structured clinical trials”


“This is so that we can learn more about whether venoplasty works and if so for how long. Further research could also investigate the relationship between MS and CCSVI, as this is very unclear at present”.

NICE’s guidance outlines what NHS healthcare professionals should do if they wish to consider percutaneous venoplasty as a treatment option, based on its safety and efficacy only. Cost is not considered in this type of guidance.




Add New Comment

Related Items


Most popular


Incraft low-profile endograft launched in Europe and Canada
Wednesday, 10 Sep 2014
Cordis announced on 10 September the launch of its Incraft AAA Stent Graft System, an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from ... Incraft low-profile endograft launched in Europe and Canada

First patient enrolled in US study of Novate’s Sentry IVC filter
Monday, 22 Sep 2014
Novate Medical has announced that Souheil Saddekni, professor of Vascular and Interventional Radiology at the University of Alabama, Birmingham, USA, has enrolled the first patient in the SENTRY IDE ... First patient enrolled in US study of Novate’s Sentry IVC filter

First drug-eluting balloon approved in USA
Friday, 10 Oct 2014
The FDA has approved the Lutonix drug-eluting balloon for the management of peripheral artery disease. This is the first time that the agency has approved such a device for this indication in the USA. First drug-eluting balloon approved in USA

Features


Not all drug-eluting balloons are equal
Wednesday, 15 Oct 2014
Thomas Zeller, Bad Krozingen, Germany, analyses the results of two recent randomised controlled trials comparing drug-eluting balloons to angioplasty alone in femoropopliteal lesions. Not all drug-eluting balloons are equal

Renal stenting may benefit patients excluded from randomised trials, says expert consensus
Wednesday, 15 Oct 2014
Sahil A Parikh, Case Western Reserve University School of Medicine, Cleveland, USA, speaks to Vascular News about the Society for Cardiovascular Angiography and Interventions expert consensus on ... Renal stenting may benefit patients excluded from randomised trials, says expert consensus

Profiles


Martin Björck
Wednesday, 01 Oct 2014
Martin Björck, Uppsala University Hospital, Sweden, holds the only professor-chair of vascular ... Martin Björck

Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions